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Abstract
Background/Aims. The concept of metaplastic and non-metaplastic types of gall bladder cancer and the likelihood of
hormone receptor expression in the nuclei of tumour cells raised the possibility of a potential role for anti-estrogen therapy
in gall bladder cancer. This study was carried out to determine the hormone receptors (ER/PR) expression level in gall
bladder cancer using specific immunohistochemical assays and correlate it with patient and tumour histopathological
characteristics. Patients and methods. Histopathological tumour specimens of 62 patients who underwent a radical
cholecystectomy were analysed. Pronase pretreatment and primary monoclonal antibodies were used to perform
immunohistochemical analysis for ER and PR. Results. The histology was adenocarcinoma  predominantly, moderately
to poorly differentiated (91%). Gallstones were present in 90% of the individuals. Of the 62 specimens analysed, 62 (100%)
and 61 (98%) were negative for ER and PR, respectively. Conclusion. The high incidence of gallstone-related gall bladder
cancer in India is associated with metaplasia and a tendency to poorer differentiation in the tumour histology. These
tumours are consequently less likely to express hormone receptors. Thus, there does not seem to be a role for anti-hormone
therapy in patients with histogenesis similar to that seen in India.
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Introduction
Gall bladder cancer has been traditionally associated
with a poor prognosis. The 5-year survival rate is
B5% [1]. India is the country with the highest
incidence of gall bladder cancer [2].
Yamamoto et al. [3] separated gall bladder cancers
into metaplastic and non-metaplastic types based
on the presence or absence of metaplastic changes
in the tumour tissues and their immediate vicinity.
They went on to show that estrogen receptor (ER)
immunoreactivity was higher in these metaplastic
tumours [4]. Nakamura et al. [5] found that increas-
ing lack of differentiation (moderately and poorly
differentiated lesions) was associated with more ER
expression in the nuclei. He concluded that such
patients could benefit from anti-hormone therapy.
These initial studies, however, lacked reproducibility.
This was evidenced by the work of Ko et al. [6], who
showed that ER expression in tumours was absent to
weak. Malik et al. [7] demonstrated that poor
differentiation was more likely to be associated with
negative ER expression. Further, lack of expression of
Er isoform at the invasive front of the tumour was
found to be associated with a more aggressive
malignancy [8]. It was because of these conflicting
reports, the high incidence of gall bladder cancer in
our country [2], and the lack of convincing and
effective adjuvant treatments for gall bladder cancer,
that we decided to undertake this study. We wanted to
study the hormone expression in gall bladder cancer
in the hope that this may provide us with data to
support the use of anti-hormone as an adjunct to
surgery to obtain better outcomes in these patients.
Patients and methods
Tumour specimens of 62 patients with gall bladder
cancer treated at the Department of Gastrointestinal
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and Hepatopancreatobiliary Surgical Oncology of the
Tata Memorial Hospital from 1 January 2005 to 31
January 2006 were analysed by immunohistochemical
assay for the expression of ER and PR status. Data for
each of the 62 patients including age, sex, liver
function tests, tumour markers (CA19-9), radiologi-
cal imaging, treatment carried out and follow-up
(whenever possible) were strictly maintained. Every
specimen was stained with haematoxylin and eosin
(H&E) to obtain the diagnosis along with staging and
differentiation.
Immunohistochemical assay was performed on all
the postoperative histopathology specimens. Paraffin-
embedded sections were dewaxed in xylene and
rehydrated in a graded series of ethanol. Microwave
antigen retrieval was done in citrate buffer (pH 6.0)
for 10 min before peroxidase quenching with 3%
H2O2 in methanol for 10 min. Primary antibodies
against ER (mouse antihuman ERa clone 1D5 code:
M 7047) and PR (monoclonal mouse anti-human PR
clone: PgR 636 code: M 3569) were incubated for 2 h
at room temperature. Biotinylated second antibody
and enzyme conjugate incubation was carried out for
45 min each. Diaminobenzidine was added and
incubated until chromogen developed. Specimens
were evaluated by the scoring system used for breast
cancer, as there is no standard scoring system in gall
bladder cancer.
Results
Patient characteristics
Of the 62 patients, 18 were males and 44 were
females. The mean age was 50.199.8 years. Fifty-
six patients (90%) had associated gallstones.
Histopathological characteristics (Table I)
The histology was adenocarcinoma  predominantly,
moderately to poorly differentiated (91%). There was
one case of papillary adenocarcinoma and there were
five cases of well differentiated cancer.
Hormone receptor status (Table II)
Of the 62 specimens analysed, 62 (100%) and 61
(98%) were negative for ER and PR, respectively.
Two specimens had level 1 and 2 expression for
ER (considered negative expression), while three
specimens had 1 and 2 expression for PR. Only
one specimen had 6 expression for progesterone
receptor. The only specimen positive for PR was seen
in a female patient. There was no correlation with
tumour stage.
Discussion
The results noted in our study, i.e. the high
incidence of gallstone disease, the tendency towards
moderately to poorly differentiated adenocarcinomas
and the lack of expression of hormone receptors,
seem to differ from the Japanese results [4,5], but are
quite similar to studies from the USA and Pakistan
[6,7]. The study by Malik et al. [7] had 30 patients
and they had even used FNAC specimens. In an
endeavour to try to explain our results, disappointing
as they may seem, we tried to analyse the molecular
and genetic developmental history of gall bladder
cancer in India and Japan. It is known that gall
bladder cancer, like colorectal cancer, undergoes
sequential histopathological and molecular changes
from in situ to invasive carcinoma [9,10]. The
aetiology of gall bladder cancer has primarily been
attributed to gallstones [11]. In India, gallstones are
quite common, especially in the North [12]. How-
ever, in Japan and China, anomalous pancreatico-
biliary duct junction (APBDJ) appears to be a
leading cause for gall bladder cancer [12,13]. The
pathogenesis of gall bladder cancer as a result of
the two aetiologies varies (Figure 1). In APBDJ, the
inciting factor for cancer is the constant irritation of
the gall bladder epithelium by the refluxing pancrea-
tic juice and the stasis of pancreatic juice in the gall
bladder [14]. The result is epithelial hyperplasia
associated with a high frequency of Kras mutations
at codon 12 [15]. The resultant metaplasia is present
to a much lesser degree and the resultant neoplasm
is more likely to be a papillary adenocarcinoma. On
the other hand, the presence of gallstones induces a
severe inflammatory reaction in the mucosa and
consequent metaplasia to the gastric or intestinal
types [16]. This ultimately leads to the development
of dysplasia and carcinoma in a sequence that
involves p53 mutations [10].
Thus, from the available data it is clear that in
countries where there is a strong association of
gallstones with gall bladder cancer, there are more
Table I. Tumour histopathology and grade.
Histopathology and grade Incidence (n62)
Papillary adenocarcinoma 1 (1.7%)
Well differentiated adenocarcinoma 5 (8.0%)
Moderately differentiated adenocarcinoma 37 (59.7%)
Poorly differentiated adenocarcinoma 19 (30.6%)
Table II. Patterns of ER and PR expression in gall bladder cancer.
ER expression PR expression Number of cases
Negative Negative 57
Negative 2 (Negative) 2
Negative 6 1
2 (Negative) 1 (Negative) 1
1 (Negative) Negative 1
Total62
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frequent mutations of p53 and consequent metaplasia
and a tendency towards poorer differentiation  a
phenomenon associated with a loss of ER/PR expres-
sion. While in regions where the predominant aetiol-
ogy is APBDJ and the changes follow the sequence
of hyperplasia to dysplasia to in situ to invasive
carcinoma along with K-ras mutations, these patients
are more likely to have papillary [17] and well
differentiated tumours and consequently, ER/PR
expression.
In fact, Misra et al. [18] have shown a near 70%
overexpression of p53 protein with a significant
correlation with gallstones. A recent pilot study has
also shown that p53 plays a critical role in tumour
progression [19].
Based on these data, we are able to explain that the
loss of hormone expression in gall bladder cancer in
our study may be a feature in countries, like India,
where the incidence of gallstone-induced gall bladder
cancer is high. This allows limited opportunity for the
role of anti-estrogen therapy.
With neoadjuvant, adjuvant, or palliative chemo-
therapy, and complementary radiotherapy having
shown poor or ill-defined outcomes [19], at this
time we believe that early detection and ra-
dical surgery continue to be the only hope for an
extended survival in patients with gall bladder cancer
[20].
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